41,521 Shares in Repligen Corporation $RGEN Bought by Generate Investment Management Ltd

Generate Investment Management Ltd bought a new stake in Repligen Corporation (NASDAQ:RGEN) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 41,521 shares of the biotechnology company’s stock, valued at approximately $4,892,000. Generate Investment Management Ltd owned about 0.07% of Repligen at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Measured Wealth Private Client Group LLC purchased a new stake in shares of Repligen during the third quarter worth about $29,000. Bayforest Capital Ltd purchased a new position in Repligen during the 4th quarter valued at about $32,000. Rachor Investment Advisory Services LLC purchased a new position in Repligen during the 4th quarter valued at about $33,000. Los Angeles Capital Management LLC bought a new position in Repligen during the 4th quarter valued at approximately $36,000. Finally, Farther Finance Advisors LLC lifted its holdings in Repligen by 61.8% in the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after buying an additional 128 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Stock Performance

Repligen stock opened at $126.57 on Tuesday. Repligen Corporation has a twelve month low of $100.99 and a twelve month high of $175.77. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $7.14 billion, a P/E ratio of 140.63, a PEG ratio of 2.54 and a beta of 1.09. The stock’s 50 day moving average is $121.81 and its 200 day moving average is $136.08.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The firm had revenue of $194.25 million for the quarter, compared to analysts’ expectations of $192.05 million. During the same quarter in the prior year, the company posted $0.39 earnings per share. The business’s revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, equities research analysts predict that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on RGEN shares. UBS Group decreased their target price on Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Canaccord Genuity Group dropped their target price on shares of Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a research report on Monday, April 20th. Wolfe Research initiated coverage on shares of Repligen in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 target price on the stock. Weiss Ratings upgraded Repligen from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, May 7th. Finally, Wall Street Zen lowered Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $164.64.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.